Insider Transactions in Q1 2024 at Eye Point Pharmaceuticals, Inc. (EYPT)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,546
-10.04%
|
$510,920
$20.67 P/Share
|
|
Mar 30
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,404
+17.32%
|
-
|
|
Feb 27
2024
|
Jay S. Duker President and CEO |
BUY
Bona fide gift
|
Indirect |
2,500
+10.0%
|
-
|
|
Feb 27
2024
|
Jay S. Duker President and CEO |
SELL
Bona fide gift
|
Direct |
2,500
-7.83%
|
-
|
|
Feb 20
2024
|
Jay S. Duker President and CEO |
BUY
Bona fide gift
|
Indirect |
20,000
+50.0%
|
-
|
|
Feb 20
2024
|
Jay S. Duker President and CEO |
SELL
Bona fide gift
|
Direct |
20,000
-38.52%
|
-
|
|
Feb 13
2024
|
Nancy Lurker |
BUY
Bona fide gift
|
Indirect |
74,681
+37.05%
|
-
|
|
Feb 13
2024
|
Nancy Lurker |
SELL
Bona fide gift
|
Direct |
74,681
-47.26%
|
-
|
|
Feb 09
2024
|
Nancy Lurker |
SELL
Payment of exercise price or tax liability
|
Direct |
14,943
-4.42%
|
$418,404
$28.8 P/Share
|
|
Feb 09
2024
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
37,534
+10.3%
|
-
|
|
Feb 09
2024
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,533
-3.24%
|
$98,924
$28.8 P/Share
|
|
Feb 09
2024
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,967
+10.2%
|
-
|
|
Feb 09
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,192
-3.47%
|
$89,376
$28.8 P/Share
|
|
Feb 09
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+10.95%
|
-
|
|
Feb 09
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,656
-3.84%
|
$102,368
$28.8 P/Share
|
|
Feb 09
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,967
+9.78%
|
-
|
|
Feb 09
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,083
-5.53%
|
$142,324
$28.8 P/Share
|
|
Feb 09
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+10.84%
|
-
|
|
Feb 02
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
209
-0.55%
|
$5,852
$28.49 P/Share
|
|
Feb 02
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209
+0.54%
|
$2,299
$11.47 P/Share
|
|
Jan 26
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,325
-22.08%
|
$1,233,125
$25.53 P/Share
|
|
Jan 26
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,325
+17.11%
|
$641,225
$13.05 P/Share
|
|
Jan 26
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
26,017
-22.92%
|
$650,425
$25.36 P/Share
|
|
Jan 26
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,017
+18.61%
|
$208,136
$8.08 P/Share
|
|
Jan 25
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-0.81%
|
$15,000
$25.0 P/Share
|
|
Jan 25
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+0.81%
|
$7,800
$13.02 P/Share
|
|
Jan 25
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
600
-0.78%
|
$15,000
$25.0 P/Share
|
|
Jan 25
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+0.78%
|
$4,800
$8.08 P/Share
|
|
Jan 24
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,300
-12.21%
|
$282,500
$25.01 P/Share
|
|
Jan 24
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,300
+10.88%
|
$90,400
$8.08 P/Share
|
|
Jan 24
2024
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
29,956
-18.11%
|
$718,944
$24.98 P/Share
|
|
Jan 24
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,251
-12.57%
|
$281,275
$25.02 P/Share
|
|
Jan 24
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,251
+11.16%
|
$146,263
$13.02 P/Share
|
|
Jan 23
2024
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
5,044
-2.96%
|
$121,056
$24.97 P/Share
|
|
Jan 23
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,135
-6.36%
|
$128,375
$25.0 P/Share
|
|
Jan 23
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,135
+5.96%
|
$66,755
$13.02 P/Share
|
|
Jan 23
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
900
-1.16%
|
$22,500
$25.0 P/Share
|
|
Jan 23
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+1.15%
|
$7,200
$8.08 P/Share
|
|
Jan 22
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
34,166
-25.3%
|
$751,652
$22.47 P/Share
|
|
Jan 22
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,166
+18.55%
|
$341,660
$10.8 P/Share
|
|
Jan 11
2024
|
Therapeutics Ocumension Director |
SELL
Open market or private sale
|
Direct |
1,910,500
-95.02%
|
$36,299,500
$19.45 P/Share
|
|
Jan 11
2024
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
1,910,500
-95.02%
|
$36,299,500
$19.45 P/Share
|
|
Jan 11
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
750,000
+9.81%
|
$14,250,000
$19.75 P/Share
|
|
Jan 09
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
105,000
+1.68%
|
$2,205,000
$21.32 P/Share
|
|
Jan 08
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,913
-38.56%
|
$481,173
$21.13 P/Share
|
|
Jan 08
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,913
+27.83%
|
$68,739
$3.26 P/Share
|
|
Jan 06
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,487
-10.95%
|
$89,740
$20.4 P/Share
|
|
Jan 06
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+27.16%
|
-
|
|
Jan 06
2024
|
Nancy Lurker |
SELL
Payment of exercise price or tax liability
|
Direct |
23,043
-11.91%
|
$460,860
$20.4 P/Share
|
|
Jan 06
2024
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
75,133
+27.97%
|
-
|